Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Earnings Outlook For Intra-Cellular Therapies
Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Wednesday, 2023-03-01. Here’s what investors…
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $70 Price Target
Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $70 price target.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Looking Into Intra-Cellular Therapies’s Return On Capital Employed
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60 million.
Illumina, Poshmark, Olo And Some Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.
Where Intra-Cellular Therapies Stands With Analysts
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:
RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $70
RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price target from $71 to $70.